Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Denali Therapeutics Inc.NASDAQ: DNLI
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization dips below year-ago levels
Q2 FY2026 depreciation & amortization of $2.65M fell 13.9% year over year, behind the +17.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.7% from the prior quarter. Over 3 fiscal years it compounded at +12.6% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -13.9% toward the trailing-twelve-month pace of +17.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 14.81M USD
- Year-over-year change
- +64.7%
- 4-year CAGR
- +14.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.81M | +64.7% |
| FY2024 | 2024-12-31 | 8.99M | -46.2% |
| FY2023 | 2023-12-31 | 16.73M | +61.1% |
| FY2022 | 2022-12-31 | 10.38M | +20.8% |
| FY2021 | 2021-12-31 | 8.59M | — |
Depreciation & Amortization vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's LTM Jun 2026 depreciation & amortization of $13.14M is the 3rd largest of the 11 companies compared; the peer median is $641K.
- Its year-over-year change of +17.5% is the 4th highest of 10, against a peer median of +4.6%.
- Depreciation & amortization amounts to 364.7% of revenue for DNLI, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $83.6M | +181.5% | +24.5% | 2.3% | |
| LTM Sep 2026 | $28.19M | +36.7% | +0.9% | 2.9% | |
| LTM Jun 2026 | $13.14M | +17.5% | +12.6% | 364.7% | |
| LTM Jun 2026 | $10.32M | +18.9% | +92.7% | — | |
| LTM Mar 2026 | $8.78M | +4.6% | — | 47.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +296.1% | 5.0% |
| LTM Sep 2026 | $282K | -51.1% | +2.5% | — | |
| LTM Mar 2026 | $251K | -0.8% | -1.0% | — | |
| LTM Sep 2026 | $133K | -16.4% | -30.6% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| LTM Jun 2026 | $0 | — | — | — | |
| Peer median (excluding DNLI) | $641K | +4.6% | +1.7% | 4.0% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 85.25M | 99.85M | 108.1M | 102.88M | 99.63M |
| Change in Working Capital | (20.41M) | (24.03M) | (289.93M) | 16.94M | 149K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.71M | 2.27M | 2.43M | 1.44M | (7.52M) |
| Other Working Capital | (24.12M) | (26.3M) | (292.36M) | 15.5M | 7.67M |
| Other Non-Cash Items | 5.76M | (4.93M) | (47.67M) | (53.73M) | (14.65M) |
| Operating Cash Flow | (211.39M) | (244.72M) | (357.99M) | (347.69M) | (412.6M) |
| Capital Expenditures | (8.5M) | (17.83M) | (12.94M) | (15.91M) | (9.5M) |
| Acquisitions (Net) | 0 | 123.55M | 0 | 0 | 0 |
| Purchases of Investments | (1.42B) | (1.12B) | (1.81B) | (1.23B) | (441.26M) |
| Sales of Investments | 1.41B | 991.49M | 2.08B | 1.16B | 706.05M |
| Other Investing Activities | 0 | (123.55M) | 0 | 0 | 0 |
| Investing Cash Flow | (21.63M) | (141.39M) | 249.31M | (88.76M) | 255.28M |
| Debt Repayment | 0 | 0 | 0 | (32.34M) | (8.17M) |
| Common Stock Issued | 19.35M | 296.22M | 17.82M | 499.25M | 197.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 14.46M | 0 | 17.39M | 0 |
| Financing Cash Flow | 19.35M | 310.67M | 17.82M | 484.3M | 189.22M |
| Effect of Forex Changes | 0 | 0 | (75K) | 0 | 0 |
| Net Change in Cash | (213.67M) | (75.43M) | (90.94M) | 47.85M | 31.9M |
| Free Cash Flow | (219.89M) | (262.55M) | (370.93M) | (363.61M) | (422.1M) |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.